Base4 Innovation Ltd. develops single molecule detection platforms for healthcare and life sciences. The firm develops DNA sequencing using techniques based on silicon chip technology which can easily be scaled up and this high-throughput technology will cut the time and cost of genetic tests, enabling them to be used much more in patient diagnosis and treatment. The company was founded by Cameron Alexander Frayling in 2007 and is headquartered in Cambridge, the United Kingdom.

PerSeptive Biosystems develops instrumentation systems and consumable products for the purification, analysis, and synthesis of biomolecules. It develops and markets instrument-based systems, reagents, software, and contract services to the life science industry and research community. Customers of PerSeptive Biosystems use these tools to analyze nucleic acids (DNA and RNA) and proteins in order to make scientific discoveries, develop new pharmaceuticals, and conduct standardized testing. Founded in 1989, PerSeptive Biosystems is based in Framingham, Massachusetts. Currently, it operates as a subsidiary of Life Technologies Corporation.

EarlyDiagnostics, Inc. is an American company located in Los Angeles, CA. The firm develops cloud-based platform for integrative bioinformatics analysis. It was founded in 2017 by Wing H. Wong, Wenyuan Li and Xianghong Jasmine Zhou. Xianghong Jasmine Zhou has been the CEO since the company founding.

Chugai Pharmaceutical Co., Ltd. engages in the research, development, manufacturing, sale, importation, and exportation of pharmaceuticals. Its operations are carried out through the Domestic and Overseas businesses. The Domestic Business covers the manufacturing, research, and development operations in Japan. The Overseas business comprises of sales and production in Europe, Taiwan and China. The company was founded by Juzo Ueno on March 10, 1925 and is headquartered in Tokyo, Japan.

Gen-9, Inc. develops internet software solutions. The company was founded in 2005 and is based in Mountain View, California.

KeyGene NV provides its partners and customers in the plant breeding industry contract research, partnerships and molecular genetic services. It delivers novel enabling technologies and applications to support companies and institutes that carry out fundamental or applied genetic genomic research and that seek to enhance the quality of their products through the improvement of their genetic material. The company was established in 1989 and is headquartered in Wageningen, the Netherlands.

The a2 Milk Co. Ltd. engages in the distribution and sale of milk and dairy products. It operates through the following segments: Australia and New Zealand, China and Other Asia, & United Kingdom and USA. The Australia and New Zealand segment receives external revenue from infant formula, milk and dairy products, along with royalty and license fee income. The China and Other Asia segment includes exporting of infant formula, milk, and dairy products. The United Kingdom and USA segment focuses on milk, and infant formula sales. The company was founded by Corran McLachlan and Howard Paterson on February 17, 2000 and is headquartered in Auckland, New Zealand.

AmberGen, Inc. is a company headquartered in Watertown, MA. The firm operates as a biotechnology company. It was founded by Kenneth Rothschild. John Gillespie is the current CEO, occupying that position since 2015.\nThe company says this about itself: AmberGen, Inc. is a privately held, Boston-area company founded in 1995 to commercialize pioneering photonic technology developed at Boston University’s Molecular Biophysics Laboratory and the Photonics Center. AmberGen’s development of proprietary peptide code photocleavable linkers (PC-Linker™) led to the early introduction of novel photocleavable reagents, such as PC-Biotin and PC-Phosphoramidites which underlie several major commercial proteomic and genomic technologies. The company’s mission is to innovate in the area of therapeutics and diagnostics by solving key problems that limit progress in medicine. AmberGen’s approach combines patented techniques in proteomics and light-based control of biomolecules.

Shanghai Laiwei Biotechnology Co., Ltd., established on 2016-09-23, Business scope includes general items:engaged in biotechnology,Technology development in the field of medical science and technology,technical consulting,technology transfer,Technical Services,Chemical raw materials and products(Removal of hazardous chemicals,Monitor Chemicals,civilian explosives,precursor chemicals),building decoration materials,Auto Parts,knitted goods,Metal Material Sales,business inquiries,Experimental analysis instrument sales,Specialty Chemicals Sales(Free of Hazardous Chemicals).(Except for projects subject to approval by law,Carry out business activities independently in accordance with the law with a business license) licensed items:Import and export;Technology Import and Export.(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments,The specific business items are subject to the approval documents or licenses of relevant departments)

Amyris NASDAQ: AMRS is a science and technology leader in the research, development and production of pure, sustainable ingredients for the Health & Wellness, Clean Beauty and Flavors & Fragrances markets. Amyris applies its exclusive, advanced technology, including state-of-the-art machine learning, robotics and artificial intelligence to engineer yeast, that when combined with sugarcane syrup through fermentation, is converted to highly pure molecules for specialty ingredients. Amyris manufactures sustainably-sourced ingredients at industrial scale for B2B partners and further distribution to 2,000 of the world's top brands, reaching more than 200 million consumers. Amyris stands by its No Compromise™ promise that everything it makes is sustainably sourced, performs better, costs less, has higher purity and is better for people and the planet than products made with existing processes. Amyris also owns Biossance – the fastest-growing, clean skincare brand in the US that delivers No Compromise™ beauty. More information about the company is available at www.amyris.com...

Fertinagro has maintained a dynamic, continuous growth policy, reaching sales figures of up to 563 million euros and more than 1,257 employees in 2014. These results have been able to achieve thanks to the work and professionalism of their employees, obtaining the financial and human resources necessary to intensify their industrial and commercial development, fulfilling their objectives at international level. The internationalization of Fertinagro grows in parallel to what the divisions of food and renewable energies of the group do, which are committed to the territory contributing to improve the quality of life of society as a whole.

MGI Tech is committed to enabling effective and affordable healthcare solutions for all. MGI produces sequencing devices, equipment, consumables and reagents to support life science research, medicine and healthcare. MGI’s multi-omics platforms include genetic sequencing, mass spectrometry and medical imaging. Providing real-time, comprehensive, life-long solutions, its mission is to advance life science tools and lead digital health innovation.

The University of California is the nation's best public university system, delivering top-notch research and innovation to California (and the world).

Gid Bio Inc. is a company headquartered in Louisville, CO, that provides cellular therapy based treatments for osteoarthritis of the knee. It was founded in 2010 by G. Patrick Maxwell, J. William Futrell, Adam J. Katz and Ramon Llull. William W. Cimino is currently the CEO of the firm.

KidneyCure Ltd. is developing proprietary cell therapies aiming to prevent progression of Chronic Kidney Disease. The scientific basis and motivation for KidneyCure’s approach was provided by a world-renowned authority in Nephrology Prof. Benjamin Dekel, through genuinely pioneering research carried in his laboratory at Sheba Medical Center in Israel, one of the world’s leading medical centers. KidneyCure’s unique 3D renal cell cluster technology is expected to significantly delay the need for dialysis and transplantation and give millions of patients an opportunity to live longer higher quality lives.

Döhler GmbH operates as a producer, marketer, and provider of technology-driven natural ingredients. Its portfolio includes natural ingredients; ingredient systems; integrated solutions; and chain value. The firm serves the food and beverage industry. The company was founded by Lorenz Döhler in 1838 and is headquartered in Darmstadt, Germany.

Zhaoqing Dahuanong Biopharmaceutical Co., Ltd., established on 2002-07-22, The business scope includes the production of veterinary vaccines;sales of veterinary drugs;Technical Services;Import and export of goods or technology(Except for the import and export of goods and technologies that are prohibited by the state or involve administrative approval).The branch produces inactivated embryotoxin vaccines;Sales of veterinary biological products.(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments)

Illumina is an innovative technology and revolutionary assays aiming the analyze genetic variation and function. These studies will help make the realization of personalized medicine possible. With such rapid advances in technology taking place, it is mission-critical to have solutions that are not only innovative, but flexible, scalable, and complete with industry-leading support and service. As a company that places a high value on collaborative interactions, rapid delivery of solutions, and prioritizing the needs of its customers, they strive to meet this challenge. Illumina's innovative, array-based solutions for DNA, RNA, and protein analysis serve as tools for disease research, drug development, and the development of molecular tests in the clinic. David R. Walt, Satnam Alag, Larry Bock, and John Stuelpnagel co-founded Illumina in San Diego, California in 1998.

Matridx focuses on molecular diagnostic technology for infectious pathogens. Matridx uses the leading diagnostic technology to promote the changes in the diagnosis of infectious diseases, to make the diagnosis more simple, more rapid, and more intelligent.